US Patent

US12427207 — Pharmaceutical formulations

Formulation · Assigned to Blue Earth Diagnostics Ltd · Expires 2041-11-27 · 16y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition containing a radiohybrid agent with specific components and pH range.

USPTO Abstract

The present invention relates to a pharmaceutical composition comprising a radiohybrid agent containing a silicon-fluoride and a chelating group wherein either the fluorine is 18 F or the chelating group contains a chelated radioactive metal, wherein the composition has a ph of 4.0-6.0 and further comprises: 0.1-200 mM citrate buffer; 1-100 mg/ml ethanol; and 5-10 mg/ml sodium chloride.

Drugs covered by this patent

Patent Metadata

Patent number
US12427207
Jurisdiction
US
Classification
Formulation
Expires
2041-11-27
Drug substance claim
No
Drug product claim
Yes
Assignee
Blue Earth Diagnostics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.